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There is evidence that survivors of childhood cancers, such as acute lymphoblastic leukemia
(ALL), have increased rates of long-term skeletal muscle dysfunction. This places them
at higher risk of physical restriction and functional impairment as well as potentially
contributing to observed increases in cardiovascular disease and insulin resistance in
later life. The mechanisms underlying these changes in skeletal muscle are unknown but
chemotherapy drugs used in treatment for ALL are strongly implicated. Normal skeletal
muscle growth, development, and function are dependent on correctly functioning muscle
satellite cells, muscle motor neurons, and muscle mitochondria. Each of these key
components is potentially susceptible to damage by chemotherapy in childhood, particularly
prolonged courses including repeated administration of combination chemotherapy. If this
chemotherapy-induced damage is not fully reversible, impairment of satellite cells, muscle
motor innervation, and mitochondria could, either singly or together, lead to the emergence
of delayed or persistent skeletal muscle dysfunction many years later. The known effects
of individual drugs used in the treatment of ALL are outlined and the need for speciﬁc
targeted studies to investigate the mechanisms underlying persistent muscle dysfunction
in survivors of ALL and other childhood cancers is highlighted.
Keywords: skeletal muscle, chemotherapy, muscle dysfunction, muscle satellite cells, motor neurons, muscle
mitochondria, cancer survivors, acute lymphoblastic leukemia
INTRODUCTION
Advances in thediagnosis and treatments for pediatric cancers over
the last 40 years have led to striking improvements in survival.
The use of modern multimodal treatment for one of the com-
monest childhood cancers, acute lymphoblastic leukemia (ALL),
has elevated 5-year survival rates from below 5% in the 1960s
(Zuelzer, 1964) to 91% in 2007 (Siegel et al., 2012). Indeed the
overall 5-year survival rate for all childhood malignancies is now
83% (Siegel et al., 2012). Although a high proportion of those
children treated for cancer will survive their disease and enter
adulthood (Oefﬁnger, 2003), it is becoming increasingly evident
that this population is at higher risk of developing health-related
problems in adult life (Oefﬁnger et al., 2006). Indeed in children
who were treated for cancer in the 1970s and 1980s and stud-
ied on average 17.5 years later, there was a relative risk of 3.3 for
developing any chronic medical condition, and 8.2 relative risk
of a severe or life-threatening condition as compared with their
siblings who did not require treatment for cancer (Oefﬁnger et al.,
2006). Thus the obvious survival beneﬁts of modern treatment
methods,must be balanced against compelling evidence that those
successfully treated for cancer in childhood have a much higher
risk of impaired health, even many years after completion of treat-
ment (Oefﬁnger et al., 2006). The mechanisms underlying these
longer term health effects are largely uncertain and may vary with
different types of treatment and possibly between different indi-
vidual patients depending on their age or stage of development and
comorbidities. In addition, tissues or organs have different pat-
terns of growth and capacities for self-renewal, which may make
them more or less susceptible to manifest delayed dysfunction or
damage long after completion of anti-cancer therapies. In this arti-
cle we will review evidence that demonstrates the likely long-term
impact of chemotherapeutic agents commonly used to treat ALL,
on skeletal muscle function. We will outline three distinct, hypo-
thetical but muscle-speciﬁc molecular mechanisms, that would
explain the observed delayed, persistent, and subacute presenta-
tion of skeletal muscle dysfunction. In addition we will discuss
the potential of some of the key chemotherapy drugs commonly
used in the treatment of childhood ALL, to cause delayed effects
on skeletal muscle. Finally we will highlight how loss of skeletal
muscle can affect both functional capacity and metabolic health
in cancer survivors, and make the case for the need for carefully
designed and speciﬁcally targeted studies. Such studies will help
better understand the global long-term effects of anti-cancer treat-
ments on skeletal muscle, and facilitate the development of safe
and effective counter-measures.
SURVIVORS OF CHILDHOOD CANCER HAVE INCREASED
LEVELS OF MUSCLE DYSFUNCTION AND WEAKNESS
Studies of survivors of childhood cancer, including a majority
who are patients treated for ALL, conﬁrm that these individuals
have signiﬁcantly increased rates of physical performance limita-
tion and frequently report restrictions in participation in activities
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needed for day-to-day functions (Ness et al., 2005), many years
after the end of treatment. These ﬁndings are also reﬂected in
results of exercise testing which demonstrate reduced maximal
exercise capacity as assessed using cycle ergometry to measure
VO2 peak and maximum work load (Talvensaari et al., 1995; van
Brussel et al., 2006; Ness et al., 2007; Järvelä et al., 2010) as well
as other timed exercise performance tests (Ness et al., 2007). Of
course reductions in maximal exercise capacity may result from
a number of factors including obesity (Oefﬁnger et al., 2003) and
deconditioning secondary to lower habitual exercise levels (Florin
et al., 2007; Warner, 2008), both of which are more common, par-
ticularly in female survivors of childhood ALL. However, there is
extensive evidence that points more speciﬁcally to skeletal muscle
dysfunction in long-term survivors of childhood cancers several
years after the end of anti-cancer therapy. This includes data
showing reduced fat-free mass measured by skinfold method (Tal-
vensaari et al., 1995) and reduced skeletal muscle mass measured
by dual-energy X-ray absorptiometry (Ness et al., 2007), in sur-
vivors of childhood ALL. Also functional skeletal muscle testing
has revealed that long-term survivors of ALL have poorer muscle
endurance, assessed using sit-up and push-up maneuvers (Hovi
et al., 1993), and reduced limb muscle strength (Hovi et al., 1993;
Talvensaari et al., 1995; van Brussel et al., 2006; Ness et al., 2007).
In addition more integrated testing of motor proﬁciency includ-
ing strength, balance, and agility were also lower in children after
treatment for ALL (Harten et al., 1984; Wright et al., 1998). Fur-
thermore the deﬁcits in exercise capacity and muscle function are
not simply secondary to impaired heart function, or because of
inactivity and deconditioning, as they are demonstrated even in
the absence of any cardiac dysfunction in cancer survivors (Järvelä
et al., 2010), and even when comparing cancer survivors with
age and sex-matched controls with similar low habitual physical
activity levels (Järvelä et al., 2010).
PATTERNS OF SKELETAL MUSCLE DEVELOPMENT RELEVANT
TO LONG-TERM CHEMOTHERAPY-INDUCED DAMAGE
Given the evidence suggesting measurable impairments in skele-
tal muscle function in long-term survivors of ALL, and taking
into account the age and developmental immaturity of the typi-
cal recipients, a number of mechanisms can be proposed which
have speciﬁc relevance to muscle tissue. In particular the pro-
posed mechanisms would lead to defects in muscle function that
would persist or emerge many months or years after anti-cancer
treatments have been completed.
IMPAIRMENT OF MUSCLE SATELLITE CELLS
During neonatal development there are rapid increases in both
muscle protein synthesis and numbers of myonuclei to sustain
muscle growth and early functional development (Davis and
Fiorotto, 2009). New muscle nuclei originate from activated, pro-
liferating muscle satellite cells that make up a high proportion
of total muscle nuclei at birth. Thereafter, data from rats and
pigs shows the proportion of muscle satellite cells declines steadily
until sexual maturity. In human muscle the total number of mus-
cle ﬁbers appears stable from childhood tomiddle age (Lexell et al.,
1992) but dramatic increases in ﬁber size (hypertrophy) leads to
a doubling of muscle cross-sectional area from childhood to early
adult life (Lexell et al., 1992). Muscle satellite cells are essential
for this hypertrophy in early development as demonstrated by
Pax7- (a muscle satellite cell marker) deﬁcient mice, which have
normal muscle ﬁber number, but severely impaired growth and
regenerative capacity after injury (Kuang et al., 2006). In addition
maintenance of themuscle satellite cell population requires appro-
priate functional signals: thus disuse or unloading of limb muscles
during development leads to accelerated loss of muscle satellite
cells (Kawano et al., 2008).
After puberty, muscle satellite cells are much less active but
can be identiﬁed in sub-sarcolemmal “niches” (Bentzinger et al.,
2012). Though quiescent, these cells retain the ability to be acti-
vated in response to a variety of stimuli, including muscle damage,
and re-enter the cell cycle and proliferate. The fate of the progeny
of this proliferation of activated muscle satellite cells is dichoto-
mous: a proportion fuse with and repair existing myoﬁbers, or in
some situations form new myoﬁbers. However, in addition, and
equally importantly, some progeny do not progress through mus-
cle differentiation but return to the quiescent state in the niche
and thus replenish the pool of muscle satellite cells available for
muscle repair functions in the future.
The median age of presentation with ALL is 4 years (Kulka-
rni et al., 2011), which coincides with the period when muscle
satellite cells are still highly active, proliferating, and contribut-
ing to muscle growth. Activated satellite cells appear to be more
susceptible than quiescent satellite cells to cytotoxic conditions
including oxidative stress (Pallafacchina et al., 2010). Thus expo-
sure of activated muscle satellite cells to DNA damaging agents
and chemotherapy-induced oxidative stress (Chen et al., 2007) in
childhood, may impair the satellite cells’ ability to proliferate and
differentiate, or to replenish the quiescent cell population. Fur-
thermore, other effects of treatment during childhood such as
enforced inactivity and possible prolonged impairment of motor
neuron function, may have additional important roles in deplet-
ing the number of satellite cells in muscle. Thus one plausible
mechanism for chemotherapy-related muscle dysfunction is that
chemotherapy treatment leads to early depletion or accelerated
senescence of muscle satellite cells. Any immediate impact of this
type of reduction in the net muscle regenerative capacity would
be very difﬁcult to detect; but failure to repair and regenerate nor-
mally after exercise-related muscle injury over an extended period,
would lead to an incremental loss of muscle ﬁbers and a premature
decrease in muscle mass.
IMPAIRED ACTIVITY OF MOTOR NEURONS OR DEPLETION OF MUSCLE
MOTOR UNITS
Each motor neuron typically innervates several muscle ﬁbers
within a given muscle, collectively known as a motor unit. The
nerve conduction velocity and the frequency and pattern of depo-
larization, as well as the density of innervation of muscle ﬁbers, all
play a role in normal skeletal muscle growth, function, and adap-
tation throughout life (Duchateau et al., 2006). During childhood,
acquisition of gross and ﬁne motor skills involves maturation of
nerve ﬁber tracts in the central nervous system through child-
hood and adolescence, which in turn facilitate development of
motor and speech functions (Paus et al., 1999). In the periph-
ery too, nerve ﬁber conduction patterns mature throughout early
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childhood, allowing both motor and sensory nerve conduction
velocities to increase to adult speeds (García et al., 2000). Neuro-
logical deﬁcits are frequently documented in children undergoing
treatment for ALL and may be due to direct or indirect effects
of the disease or treatments including drugs such as vincristine
(see below) and cranial irradiation (Vainionpää, 1993). Periph-
eral neuropathy and impairment in ﬁne and gross motor skills,
including walking, are reported in up to 30% of patients after
2–3 years of therapy (Vainionpää, 1993). While defects such as
peripheral neuropathy may be transient and recover over time
after completion of treatment, subacute sequelae of the impair-
ments in nerve function and development during childhood, may
lead to other secondary effects. Thus children diagnosed with ALL
at a young age are at a higher risk for developing restricted joint
range of motion, and other chronic changes such as contractures
years after completing treatment (Wright et al., 1998). In addition
cranial radiotherapy for central nervous system disease, may indi-
rectly impede muscle development and growth through damaging
effects on the development of central neural tracts, and via impacts
on the hypothalamic-pituitary axis leading to deﬁciencies in hor-
mones, such as growth hormone, that are important for muscle
anabolism (Skinner, 2012a).
During normal aging, and in some primary muscle or neuro-
logical diseases, the density of innervation of muscle ﬁbers is pro-
gressively reduced through cycles of denervation and incomplete
re-innervation (McComas et al., 1993). Eventually the regenera-
tive capacity of motor neuron terminal axons is exceeded leading
to loss of motor units, accumulation of severely atrophied ﬁbers,
and ﬁnally loss of muscle ﬁbers (Deschenes, 2004). This heralds an
inexorable loss of muscle mass, strength, and functional capacity.
Several anti-cancer treatments, including chemotherapies used in
ALL (see below), have the potential to cause motor neuropathies
(Balayssac et al., 2011). Given this potential for chemotherapy-
induced neural damage, it is also possible that after completing
treatment for ALL,muscle ﬁbers are less densely innervated which
leaves them more susceptible to accelerated denervation of aging.
This in turn would leave affected patients more likely to develop
muscle weakness, wasting, and physical frailty earlier or more
rapidly than their peers. Thus another mechanistic hypothesis for
long-term muscle dysfunction after treatment for ALL would be
that sub-clinical, generalized, chemotherapy-related damage to
motor neurons or neuromuscular junctions, promotes progressive
denervation-related muscle loss.
IMPAIRED MUSCLE MITOCHONDRIAL FUNCTION
Mitochondria in muscle are essential sources of energy (ATP) for
performance of external contractile work, but are also involved
in any other aspects of muscle tissue homeostasis including reg-
ulating atrophy pathways and apoptosis (Marzetti et al., 2010).
Normal mitochondrial biogenesis and functioning is dependent
on tightly regulated expression of genes encoded on both nuclear
and mitochondrial (mt) DNA. mtDNA is susceptible to damage
by oxidative stress (Doria et al., 2012) and mutates at higher rates
than nuclear DNA (Barja and Herrero, 2000). Deletion muta-
tions in mtDNA can affect expression of mitochondrial proteins
including components of the electron transport chain, resulting
in impaired mitochondrial function, and have been observed in
many different diseases (Lax et al., 2011; Medikayala et al., 2011).
To cause functional defects in muscle the proportion of affected
mtDNA molecules and mitochondria must reach a certain thresh-
old (Park and Larsson, 2011). mtDNA deletions are propagated
through mtDNA replication and mitochondrial biogenesis within
muscle and can be ampliﬁed in over time such that the thresh-
old causing detectable mitochondrial functional defects is reached
several months or years later.
Many anti-cancer treatments including cytotoxic chemothera-
pies, induce cell death by disrupting normal nuclear DNA repair
and replication. In mononucleated cells this leads to cessation
of proliferation and cell death (along with associated loss of any
cellular mitochondria and mtDNA), which is the basis for the
anti-cancer activity of such drugs. However, in post-mitotic mult-
inucleated muscle ﬁbers, damaged nuclear DNA can be cleaved
and degraded, without loss of all the other cellular contents,
and thus it is possible that acquired mutated mtDNA can persist
and accumulate, even if myonuclei containing mutated nuclear
DNA are removed. There is evidence that those treated with
intensive combined anti-cancer chemotherapy and radiation have
increases levels of mutations in muscle mtDNA months or years
later (Wardell et al., 2003). However, any functional impact of
such mutations might take some years to become evident through
mtDNA replication, and progressive ampliﬁcation of mtDNA
mutation load over time. This may be the explanation for ﬁnd-
ings from a small post-mortem study in humans who died only a
few weeks or months after their last treatment. In this study there
was evidence of acute cardiac muscle mitochondrial structural
and DNA damage, but no evidence of skeletal muscle mito-
chondrial ultrastructural changes or mitochondrial functional
defects (Lebrecht et al., 2005). Thus another hypothesis to explain
how chemotherapy in childhood for ALL may lead to delayed
skeletal muscle functional impairment, is through progressive
ampliﬁcation and propagation of chemotherapy-induced mtDNA
mutations leading to delayed muscle mitochondrial dysfunction.
CHEMOTHERAPEUTIC AGENTS THAT MAY INDUCE
LONG-TERM SKELETAL MUSCLE DYSFUNCTION IN ALL
The fact that the deﬁcits in maintenance of skeletal muscle and
function occur or persist many years after successful treatment for
childhood cancers such as ALL, strongly suggests that anti-cancer
treatments themselves are implicated in causing the skeletalmuscle
dysfunction described. Direct effects of systemically adminis-
tered chemotherapeutic agents, which circulate to all tissues in
the blood, are prime candidates. Non-tumor tissues, including
skeletal muscle, are exposed to a variety of chemotherapy-related
toxic effects over the course of treatment with most standard
chemotherapy regimes. These include repeated cycles of acute
exposure to high levels of oxidative stress (Chen et al., 2007)which,
if not controlled by endogenous anti-oxidant defenses, can mod-
ify many different macromolecules (nucleic acids, proteins, lipids)
and disrupt a wide range of cellular functions. Furthermore many
anti-cancer treatments also induce DNA damage through a vari-
ety of more direct mechanisms (Jackson and Bartek, 2009). Both
these types of cellular toxicity are potentially relevant in initiating
changes in muscle tissue in childhood, which lead to the long-term
functional deﬁcits described.
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Many of the chemotherapy drugs used for treatment of ALL in
the 1980s and 1990s remain in use today because they are used in
treatment regimes that achieve very good survival rates (Siegel
et al., 2012). Induction combination chemotherapy commonly
includes treatment with vincristine, corticosteroids, asparaginase
and an anthracycline (Pui and Evans, 2006). For all of these drugs,
except asparaginase, there is evidence of short-term effects on
muscle for each drug individually, as detailed below. However,
it should be stressed that the potential synergistic interactions
between these and other agents when given concurrently, and the
nature of any latent effects on muscle, months or years beyond the
period of chemotherapy, are much less clear.
Vincristine is a vinca alkaloid that disrupts microtubules and
arrests cell cycle division (Jordan et al., 1985) and is highly active
in treatment of ALL. Disruption of microtubular axonal transport
is also thought to explain the main side-effects of vincristine treat-
ment, including sensory neuropathy and neuropathic pain, but
this drug can also cause motor and autonomic neuropathy (Moore
and Pinkerton, 2009; Balayssac et al., 2011). Musculoskeletal
abnormalities including neuropathic-induced contractures have
been reported in children previously treated for leukemia with
vincristine (Ryan and Emami, 1983). The side-effects vary greatly
with each individual, and earlier reports suggested the neuropathy
was largely reversible on completion of treatment (Rosenthal and
Kaufman, 1974). However, more recent reports have documented
mobility and musculoskeletal impairments in long-term survivors
of ALL, and identiﬁed that higher cumulative doses of vincristine
increase the risk for such persisting neuromuscular defects (Ness
et al., 2012).
Glucocorticoids, including drugs such as dexamethasone and
prednisone, are frequently used for their anti-emetic properties
around the time of chemotherapy (Jordan et al., 2011), but higher
and more prolonged courses are used for their proven speciﬁc
anti-neoplastic role in hematological malignancies such as ALL
(Pui and Evans, 2006). During administration of glucocorticoids,
especially prolonged courses or higher doses, skeletal muscle atro-
phy can be expected in 40–60% of patients (Batchelor et al., 1997;
Lee et al., 2006). Steroid myopathy is more pronounced in proxi-
malmuscles and fast twitch (type II) ﬁbers (Schakman et al., 2008).
Muscle wasting is initially due to activation of muscle proteolysis
(Baehr et al., 2011) and later due to insulin resistance and impaired
muscle protein synthesis and anabolism (Menconi et al., 2007).
Also recent data in myotube culture shows that glucocorticoids
promote muscle-speciﬁc gene expression (Pansters et al., 2012)
and this property could conceivably disrupt the ability of a pro-
portion of muscle satellite cells to return to the undifferentiated
quiescent state after initial proliferation. Finally corticosteroids
increase appetite and this and other metabolic changes frequently
results in obesity in children undergoing treatment for ALL,
though in many children percentage body fat and body com-
position improves when treatment is completed (van der Sluis
et al., 2002). While it is not clear whether high dose glucocor-
ticoids contribute to long-term muscle dysfunction, in children
treated for ALL, there is evidence from adults that prolonged
corticosteroid use can induce muscle mitochondrial dysfunction
and increased oxidative damage to both nuclear and mtDNA
(Mitsui et al., 2002).
Anthracyclines, such as doxorubicin, bind DNA avidly and
preferentially accumulate in nuclei and mitochondrial. The DNA-
bound drug interferes with nuclear DNA transcription and
replication, and thus inhibits cell growth and division (Gewirtz,
1999). These highly effective anti-cancer agents are still rou-
tinely used in ALL, particularly in children with less responsive
disease; but anthracyclines are also known to cause potentially
life-threatening cardiomyopathy (Octavia et al., 2012), and the fre-
quency and severity of this cardiotoxicity increases with higher
cumulative doses (Ewer and Ewer, 2010). Cardiac muscle toxic-
ity of anthracyclines is mediated through increased production
of reactive oxygen species (ROS) by cardiac muscle mitochon-
dria (Octavia et al., 2012), and increased intracellular calcium
levels which may promote ROS production and impair contrac-
tile function (Octavia et al., 2012). Direct mtDNA binding by
anthracyclines and increased mitochondrial ROS production may
both contribute to observed increased mtDNA damage which
accumulates with repeated treatments (Serrano et al., 1999). Dif-
ferent tissues accumulate anthracycline-induced mtDNA damage
at varying rates, but in rats increased mtDNA mutations, defec-
tive mitochondrial respiratory enzyme activity and increased ROS
production are observed in cardiac (Lebrecht et al., 2003) and renal
(Lebrecht et al., 2004) tissues, 6–7 months after the end of treat-
ment. Early studies suggested skeletal muscle was not a target
for acute anthracycline-induced damage (Ito et al., 1990) or mito-
chondrial dysfunction or ultrastructural changes (Lebrecht et al.,
2003). However, in contrast, there are recent data from tissue
culture and rodent studies which demonstrate that acute admin-
istration of doxorubicin, induces skeletal muscle mitochondrial
ROS, increases proteolysis and leads to muscle weakness (Gilliam
et al., 2009, 2012; Gilliam and St Clair, 2011). As a result, though
acute toxicity has been demonstrated experimentally in skeletal
muscle, it is still uncertain whether anthracyclines used in treat-
ment of childhood ALL also induce persistent long-term skeletal
muscle dysfunction, either through mtDNA mutations and defec-
tive respiration, or other mechanisms such as altered calcium
handling (van Norren et al., 2009).
Other anti-cancer chemotherapy drugs have also been associ-
ated with skeletal muscle dysfunction but for many of them the
evidence of a direct effect on skeletal muscle is currently less per-
suasive than for the agents discussed above. For example retrospec-
tive analyses have linked the use of methotrexate (Ness et al., 2012)
and asparaginase (Hovi et al., 1993) with the development of more
severe persistent musculoskeletal limitations in survivors of ALL.
Other reports have implicated cytosine arabinoside as a causative
agent in acute severe muscle damage after treatment for ALL
(Morales-Polanco et al., 1997). In addition newer targeted drugs
such as the tyrosine-kinase inhibitor, Imatinib, are being investi-
gated as potentially useful treatments for maintenance therapy in
ALL (Rives et al., 2011). However, there is not yet enough clini-
cal follow-up data to know whether these newer drugs also have
deleterious long-term impacts on skeletal muscle or other tissues.
Thus, it remains possible that the speciﬁc agents discussed above,
and others used in the treatment of ALL have a synergistic impact
on muscle, and it is self-evident that distinguishing the precise role
of each drug in causing long-term muscle dysfunction is extremely
challenging. Nevertheless, from a therapeutic standpoint
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the more important question is not whether each individual drug
does or does not damage skeletal muscle, but (a) what is the nature
of the impact of the combination treatments being employed
for ALL? and (b) how can any deleterious effects on muscle be
avoided or minimized? If it is true that chemotherapy given in
childhood causes long-term muscle dysfunction, and given that
current treatment regimes lead to very high cure rates for ALL,
we can anticipate that these agents will continue to be used,
and thus will likely cause long-term muscle dysfunction in the
growing number of adults who will survive current treatment
of ALL.
THE BROADER IMPLICATIONS OF LONG-TERM
CHEMOTHERAPY-INDUCED SKELETAL MUSCLE
DYSFUNCTION
As discussed above there is compelling evidence that, as a group,
children who have successfully completed treatment for ALL (or
indeed other childhood cancers), have diminished health status
as adults. Furthermore, a higher proportion of these individuals
will also have reduced muscle strength and function. Although the
mechanisms underlying the observed muscle dysfunction are not
clear, it is likely that chemotherapy treatments have an important
direct role. The growing awareness of the late effects of cancer
and cancer treatments has stimulated calls to establish long-term
surveillance for the survivors of pediatric cancers (Aslett et al.,
2007; Oefﬁnger et al., 2010; Prasad et al., 2010; Skinner, 2012b). If
successful such programs will allow more systematic identiﬁcation
and characterization of affected individuals, and will hopefully
facilitate studies to investigate the hypotheses proposed here and
to initiate potential intervention studies.
Long-term chemotherapy-induced toxicity in skeletal muscle
is relatively poorly studied, despite the importance of this tis-
sue in determining mobility and physical function. Furthermore,
skeletal muscle serves metabolic as well as contractile functions,
including being a principal site of lipid oxidation and glucose
uptake, and thus a major determinant of insulin sensitivity. Hence
chemotherapy-induced loss of skeletal muscle mass, or other types
of skeletal muscle dysfunction, may make a direct or indirect con-
tribution to the increased morbidity secondary to chronic medical
conditions (Oefﬁnger et al., 2006) such as obesity (Oefﬁnger et al.,
2003; Curry et al., 2006), cardiovascular disease (Nagarajan et al.,
2011), and metabolic syndrome (Talvensaari et al., 1996), which
are observed in pediatric cancer survivors. Moreover some, or all,
of the chemotherapy-induced effects on muscle tissue discussed
above in children, may also be relevant to the far larger number
of adults undergoing chemotherapy treatment. If this is true, it
follows that functional and metabolic limitations due to skeletal
muscle dysfunction are also leading to increased morbidity and
mortality in long-term survivors of adult cancers; but that these
chemotherapy-related effects are currently being misattributed to
aging or other chronic degenerative diseases.
FUTURE DIRECTIONS
For now the mechanisms by which skeletal muscle dysfunction
occur in survivors of childhood cancer (or in adults) remains an
open question. But this question can only be answered by spe-
ciﬁc targeted studies. We have outlined three cellular mechanisms
for long-term muscle dysfunction involving impairment of mus-
cle satellite cells, muscle denervation, and muscle mitochondrial
dysfunction. These mechanisms, have speciﬁc relevance to mus-
cle tissue and are all plausible sequelae of intensive chemotherapy
treatment, particularly in childhood. New studies to test these
hypotheses in robust experimental models and, most importantly,
in cancer survivors, are nowneeded. Experimentalmodels, includ-
ing animal models, can help verify whether any of the mechanistic
hypotheses set out above canbe conﬁrmed. However, animalmod-
els can only go so far in replicating the impact of 10–15 years of
survival after cancer therapy in humans. Thus carefully designed
clinical studies, incorporating muscle biopsies of adult survivors
of childhood ALL will be required for ﬁnal conﬁrmation. With-
out such studies, the true cause of the underlying skeletal muscle
impairments in these patients will continue to be missed, and this
will greatly impede any attempts to devise successful treatment
strategies.
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